CAS 1413431-07-8

N-(2-(tert-Butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

CAS : 1413431-07-8

N-(2-(tert-Butyl)-5-hydroxy-4-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

Formule : C₂₄H₁₉D₉N₂O₃

Degré de pureté : 99.83%

Masse moléculaire : 401.55

Ref: 54-DE2781

Ivacaftor-D9

CAS : 1413431-07-8

Ivacaftor-D9

Formule : C₂₄H₁₉D₉N₂O₃

Degré de pureté : ≥98%

Masse moléculaire : 401.55

Ref: 54-DE3567

Ivacaftor-d9

CAS : 1413431-07-8

Formule : C₂₄H₁₉D₉N₂O₃

Masse moléculaire : 401.55

Ref: 4Z-I-056038

Ivacaftor (4-tertbutyl-d9) (Major)

Produit contrôlé

CAS : 1413431-07-8

Formule : C₂₄H₁₉D₉N₂O₃

Couleur et forme : Neat

Masse moléculaire : 401.55

Ref: TR-I940603

Ivacaftor-D9

CAS : 1413431-07-8

Ivacaftor-D9 is a deuterated compound of ivacaftor used for isotope tracing. Ivacaftor is an effective, orally administered CFTR modulator, cystic fibrosis.

Formule : C₂₄H₁₉D₉N₂O₃

Degré de pureté : 99.13%

Couleur et forme : White Solid

Masse moléculaire : 401.55

Ref: TM-T27098

Ivacaftor (4-tertbutyl-d9) (major)

CAS : 1413431-07-8

Ivacaftor is a drug substance with the molecular formula C17H20Cl2O3, a monocarboxylic acid amide. Ivacaftor is indicated as a treatment for cystic fibrosis (CF) in patients age 12 years and older who have one of the following mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or R117C. Ivacaftor binds to and activates the CFTR protein by increasing its stability and function. The carboxyl terminal domain of CFTR is required for interaction with ivacaftor. Ivacaftor also potentiates the activity of chromenes such as ivacaftor (4-tertbutyl-d9) and other cftr potentiators such as VX-770. These compounds are being studied in cancer treatment because they may be able to

Formule : C₂₄H₂₈N₂O₃

Degré de pureté : Min. 95%

Masse moléculaire : 401.5 g/mol

Ref: 3D-NGC43107